Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Denali scores record-breaking $217mm Series A financing

Executive Summary

In the largest biopharma Series A round to date, Fidelity Biosciences, Arch Venture Partners, Flagship Ventures, the Alaska Permanent Fund (represented by Crestline Investors), sovereign wealth funds, public mutual funds, and private family offices committed $217mm in Series A financing for Denali Therapeutics Inc. (neurodegenerative diseases). Fidelity, Arch, and Flagship have representation on the start-up's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies